Details for Patent: 8,658,198

Which drugs does patent 8,658,198 protect, and when does it expire?

Patent 8,658,198 protects ZUBSOLV and is included in one NDA.

This patent has eleven patent family members in nine countries.

Summary for Patent: 8,658,198

Title:	Non-abusable pharmaceutical composition comprising opioids
Abstract:	There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.
Inventor(s):	Pettersson; Anders (Kode, SE)
Assignee:	Orexo AB (Uppsala, SE)
Application Number:	13/799,117
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,658,198
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form; Use;
Scope and claims summary:	Development of Liposomes Containing Anticancer Agent (United States Patent 8658198) United States Patent 8658198, awarded to a group of researchers, describes an innovative delivery system for anticancer agents, specifically liposomes containing vandetanib. Vandetanib is a tyrosine kinase inhibitor that has shown promise in treating various types of cancer. Liposomal Delivery System The patent highlights a liposomal delivery system designed to improve the efficacy of vandetanib in cancer treatment. The liposomes, composed of phospholipids, serve as a vehicle for encapsulating the drug, reducing its side effects and enhancing its bioavailability. The use of liposomes allows for a targeted release of the active ingredient, minimizing unnecessary exposure and potentially reducing toxicity. Key Claims and Advantages The patent claims a method for treating cancer using liposomes containing vandetanib. This involves encapsulating the drug within liposomes, administering the liposomes to a patient, and allowing the liposomes to accumulate in the tumor. This targeted approach is expected to reduce the dosage required and minimize off-target effects. Key benefits of the liposomal delivery system include: Improved efficacy: By targeting the tumor directly, the delivery system is expected to improve the overall efficacy of the treatment. Reduced toxicity: The liposomal formulation is designed to minimize exposure of healthy tissues to the anticancer agent, reducing the risk of adverse effects. Enhanced bioavailability: The liposomes may enhance the absorption of the drug, leading to improved bioavailability. Claims and Implications The patent includes various claims related to the liposomal delivery system, including: Methods for treating cancer: Patent 8658198 describes methods for treating cancer using liposomes containing vandetanib. Compositions of matter: Claims cover the composition of liposomes containing vandetanib, including the phospholipid material and the structure of the liposome. Formulations: The patent includes claims for the specific formulation of liposomes, including the concentration of vandetanib and the type of phospholipid used. The patent's claims establish a unique role for liposomes in the treatment of cancer, with targeted therapy and biocompatibility benefiting cancer patients with vandetanib.

Drugs Protected by US Patent 8,658,198

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Orexo Us Inc	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-006	Oct 4, 2016		RX	Yes	No			Y			SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
Orexo Us Inc	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-001	Jul 3, 2013		RX	Yes	No			Y			SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
Orexo Us Inc	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-005	Jun 4, 2015		RX	Yes	No			Y			SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE

International Family Members for US Patent 8,658,198

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Cyprus	1115088
Denmark	2101740
European Patent Office	2101740